|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Betaxolol#Warnings]] |
| {{Betaxolol}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Warnings and Precautions==
| |
| | |
| Topically applied beta-adrenergic blocking agents may be absorbed systemically. The same adverse reactions found with systemic administration of beta-adrenergic blocking agents may occur with topical administration. For example, severe respiratory reactions and cardiac reactions, including death due to bronchospasm in patients with asthma, and rarely death in association with [[cardiac failure]], have been reported with topical application of beta-adrenergic blocking agents.
| |
| | |
| BETOPTIC® Ophthalmic Solution has been shown to have a minor effect on heart rate and blood pressure in clinical studies. Caution should be used in treating patients with a history of [[cardiac failure]] or heart block. Treatment with BETOPTIC Ophthalmic Solution should be discontinued at the first signs of [[cardiac failure]].
| |
| | |
| ===PRECAUTIONS===
| |
| | |
| ====General====
| |
| | |
| Information for Patients. Do not touch dropper tip to any surface as this may contaminate the solution.
| |
| | |
| ====Diabetes Mellitus====
| |
| | |
| Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous [[hypoglycemia]] or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. Beta-adrenergic receptor blocking agents may mask the signs and symptoms of acute [[hypoglycemia]].
| |
| | |
| ====Thyrotoxicosis====
| |
| | |
| Beta-adrenergic blocking agents may mask certain clinical signs (e.g., tachycardia) of hyperthyroidism. Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents, which might precipitate a thyroid storm.
| |
| | |
| ====Muscle Weakness====
| |
| | |
| Beta-adrenergic blockade has been reported to potentiate muscle weakness consistent with certain myasthenic symptoms (e.g., [[diplopla]], [[ptosis]], and generalized weakness).
| |
| | |
| ====Major Surgery====
| |
| | |
| Consideration should be given to the gradual withdrawal of beta-adrenergic blocking agents prior to general anesthesia because of the reduced ability of the heart to respond to beta-adrenergically mediated sympathetic reflex stimuli.
| |
| | |
| ====Pulmonary====
| |
| | |
| Caution should be exercised in the treatment of glaucoma patients with excessive restriction of pulmonary function. There have been reports of asthmatic attacks and pulmonary distress during betaxolol treatment. Although rechallenges of some such patients with ophthalmic betaxolol has not adversely affected pulmonary function test results, the possibility of adverse pulmonary effects in patients sensitive to beta blockers cannot be ruled out.
| |
| | |
| ====Risk from Anaphylactic Reaction====
| |
| | |
| While taking beta-blockers, patients with a history of atopy or a history of severe anaphylactic reaction to a variety of [[allergen]]s may be more reactive to repeated accidental, diagnostic, or therapeutic challenge with such [[allergen]]s. Such patients may be unresponsive to the usual doses of [[epinephrine]] used to treat [[anaphylactic reaction]].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = BETOPTIC (BETAXOLOL HYDROCHLORIDE) SOLUTION/ DROPS [ALCON] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=31b9b263-11fd-4495-83dd-ababf0d70e9e | publisher = | date = | accessdate = 3 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
|
| |
|
| [[Category:Beta blockers]] | | [[Category:Beta blockers]] |
| [[Category:Cardiovascular Drugs]] | | [[Category:Cardiovascular Drugs]] |
| [[Category:Drugs]] | | [[Category:Drugs]] |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |